These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 18481387)
1. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Weide B; Carralot JP; Reese A; Scheel B; Eigentler TK; Hoerr I; Rammensee HG; Garbe C; Pascolo S J Immunother; 2008; 31(2):180-8. PubMed ID: 18481387 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
3. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242 [TBL] [Abstract][Full Text] [Related]
4. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071 [TBL] [Abstract][Full Text] [Related]
5. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002 [TBL] [Abstract][Full Text] [Related]
6. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257 [TBL] [Abstract][Full Text] [Related]
7. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362 [TBL] [Abstract][Full Text] [Related]
8. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763 [TBL] [Abstract][Full Text] [Related]
10. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645 [TBL] [Abstract][Full Text] [Related]
11. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Kyte JA; Kvalheim G; Aamdal S; Saebøe-Larssen S; Gaudernack G Cancer Gene Ther; 2005 Jun; 12(6):579-91. PubMed ID: 15818380 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345 [TBL] [Abstract][Full Text] [Related]
13. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171 [TBL] [Abstract][Full Text] [Related]
14. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma. Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012 [TBL] [Abstract][Full Text] [Related]
15. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391 [TBL] [Abstract][Full Text] [Related]
17. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
19. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]